Our Research

TRL is an independent subsidiary of Mitsubishi Tanabe Pharmaceutical Corporation (MTPC) whose role is to discover and develop potential biological drug candidates for therapy in autoimmune diseases.

TRL discontinued its research on small molecules in January 2010 and redirected its focus towards biological agents. The ‘New TRL’ reopened in the spring of 2010 with an emphasis on immunological and molecular biology approaches to lead identification.

Currently, TRL’s efforts will be directed towards antibody and antibody related research to target specific immune cells and soluble factors, as well as investigating new methods for modulating immune cell functions. TRL will establish collaborative relationships with other companies and academic research organizations to further its goals of identifying lead preclinical compounds for further development.

We will continue to consolidate our presence in immunology in the short term and expand into other areas, including oncology, in the future.